Evidence map›Paper›PMID 40975524›Full record

ArticleKidney international2025

Where next for potassium binders in hemodialysis?

Katherine Scovner Ravi, Finnian R Mc Causland

Abstract read
In one paragraph

Article in Kidney international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katherine Scovner RaviRenal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
Finnian R Mc CauslandRenal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. Electronic address: fmccausland@bwh.harvard.edu.

Funding

Association of Dialysate Bicarbonate with Hemodynamic Instability and ArrhythmiaK23DK127248 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Katherine Scovner Ravi · 2022 to 2026
$1.1M
Incident Hemodialysis Electrolyte Analysis and Rhythm Trends (IHEART)R03DK144241 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI RAVI, KATHERINE SCOVNER · 2025 to 2025
$269k
NIDDK NIH HHS K23 DK127248NIDDK NIH HHS R03 DK144241
6 · The paper itself

Abstract

Patients on hemodialysis frequently experience hyperkalemia, a condition linked to arrhythmia and mortality. The DIALIZE-Outcomes trial was designed to investigate whether the oral potassium binder, sodium zirconium cyclosilicate, could reduce cardiovascular events. The trial was terminated early because of low event accrual and high rates of medication discontinuation. From the available data, no difference in outcomes was observed, despite better potassium control. We discuss the strengths and limitations of the trial and highlight considerations for future studies.

Indexed as

Chelating AgentsHyperkalemiaKidney Failure, ChronicPotassiumRenal DialysisSilicatesHumansRandomized Controlled Trials as TopicTreatment OutcomeChelating AgentsPotassiumSilicatessodium zirconium cyclosilicate

Identifiers

PMID40975524
PMCPMC13215395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.